MET and neoplasm: In contrast, the MET‐high subtype is characterised by high MET expression and, thus, is potentially responsive to small‐molecule tyrosine kinase inhibitors; the lack of immunocyte infiltration suggests this subtype is a ‘cold’ immune tumour type.